Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Hyaluronan–cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery

Authors Tsai S , Yu D, Tsao S, Hsu F

Received 11 April 2013

Accepted for publication 10 May 2013

Published 3 July 2013 Volume 2013:8(1) Pages 2399—2407

DOI https://doi.org/10.2147/IJN.S46613

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Shiao-Wen Tsai,1 Ding-Syuan Yu,2 Shu-Wei Tsao,1 Fu-Yin Hsu2,3

1Graduate Institute of Biochemical and Biomedical Engineering, Chang Gung University, Taoyuan, Taiwan; 2Department of Life Science, 3Institute of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung, Taiwan

Abstract: Hyaluronan–cisplatin conjugate nanoparticles (HCNPs) were chosen as colon-targeting drug-delivery carriers due to the observation that a variety of malignant tumors overexpress hyaluronan receptors. HCNPs were prepared by mixing cisplatin with a hyaluronan solution, followed by dialysis to remove trace elements. The cells treated with HCNPs showed significantly lower viability than those treated with cisplatin alone. HCNPs were entrapped in Eudragit S100-coated pectinate/alginate microbeads (PAMs) by using an electrospray method and a polyelectrolyte multilayer-coating technique in aqueous solution. The release profile of HCNPs from Eudragit S100-coated HCNP-PAMs was pH-dependent. The percentage of 24-hour drug release was approximately 25.1% and 39.7% in pH 1.2 and pH 4.5 media, respectively. However, the percentage of drug released quickly rose to 75.6% at pH 7.4. Moreover, the result of an in vivo nephrotoxicity study demonstrated that Eudragit S100-coated HCNP-PAMs treatment could mitigate the nephrotoxicity that resulted from cisplatin. From these results, it can be concluded that Eudragit S100-coated HCNP-PAMs are promising carriers for colon-specific drug delivery.

Keywords: hyaluronan, cisplatin, pectin, alginate, pH-dependent, drug delivery

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.